{"id":"W4407038077","doi":"10.3389/fonc.2024.1544394","title":"Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors","year":2025,"lang":"en","type":"erratum","venue":"Frontiers in Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AbbVie","keywords":"Antibody; Medicine; Cancer research; Antibody therapy; Pharmacology; Antibody response; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002496598,0.002127224,0.002333915,0.001922825,0.001380507,0.00296834,0.002932537,0.00608803,0.1241744],"category_scores_gemma":[0.01475994,0.001316007,0.002977289,0.001218393,0.001151307,0.001343925,0.001291504,0.007524751,0.08533524],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004750134,"about_ca_system_score_gemma":0.002568523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009439285,"about_ca_topic_score_gemma":0.01893159,"domain_scores_codex":[0.9967909,0.0004813945,0.0003402937,0.0003346075,0.001716974,0.0003357781],"domain_scores_gemma":[0.9859285,0.002720574,0.001134362,0.0007669983,0.008507716,0.0009418175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002748025,0.000005616376,0.00001868052,0.00003313576,0.000003894355,0.00001620854,0.000001648348,0.00001462685,0.00005197215,0.00003157683,0.9982505,0.001544597],"study_design_scores_gemma":[0.0001583635,0.0001113314,0.00157389,0.0001884126,0.00005249817,0.0002683435,0.00002098672,0.0002529338,0.001002907,0.0003702747,0.9959715,0.00002856364],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0004627275,0.004728694,0.001584966,0.111927,0.8486892,0.0002076062,0.005809973,0.002948653,0.02364125],"genre_scores_gemma":[0.01163575,0.01074427,0.0042757,0.2495948,0.3574528,0.000630446,0.01398542,0.002597218,0.3490836],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.1241744,"threshold_uncertainty_score":0.4154048,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01280886668811133,"score_gpt":0.3334175595323087,"score_spread":0.3206086928441974,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}